سعر بيدريفيدا 500مجم اكس ال 14 قرص 2026

Clarithromycin 500 mg extended-release (XL) film-coated tablets, pack of 14 (2 strips); macrolide antibiotic (Mash Premiere, Egypt).

• Acute bacterial exacerbation of chronic bronchitisPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Acute maxillary sinusitisPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Community-acquired pneumoniaPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Most frequent in clinical trials (adults and children): abdominal pain, diarrhoea, nausea, vomiting and dysgeusia; also dyspepsia, abnormal liver function tests, anaphylactic reaction, candidiasis, headache, insomnia and rash.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Post-marketing: hepatotoxicity, QT prolongation/torsades de pointes, severe skin reactions, hypoglycaemia (with hypoglycaemic agents or insulin), rhabdomyolysis (often with statins, fibrates, colchicine or allopurinol), parosmia/anosmia/ageusia, convulsions and psychiatric events.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to clarithromycin, erythromycin or any macrolide antibacterial.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Concomitant cisapride or pimozide (QT prolongation, ventricular arrhythmias including torsades de pointes; fatalities reported).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• History of cholestatic jaundice or hepatic dysfunction associated with prior clarithromycin use.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Severe acute hypersensitivity reactions (anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, Henoch-Schonlein purpura, AGEP): discontinue immediately and treat.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• QT prolongation and torsades de pointes: avoid in known QT prolongation or ventricular arrhythmia, with QT-prolonging drugs, uncorrected hypokalemia/hypomagnesemia, significant bradycardia, or class IA/III antiarrhythmics; elderly patients may be more susceptible.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hepatotoxicity (hepatic dysfunction, hepatitis, rarely fatal hepatic failure): discontinue if signs and symptoms of hepatitis occur.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• CYP3A substrates (e.g., carbamazepine and other narrow-therapeutic-index drugs)Clarithromycin inhibits CYP3A and can raise their concentrations; use with caution, adjust dose and monitor levels where appropriate.DailyMed (U.S. National Library of Medicine)
• ColchicineIncreased colchicine exposure with potentially fatal toxicity (especially in elderly and renal impairment); contraindicated in renal or hepatic impairment.DailyMed (U.S. National Library of Medicine)
• HMG-CoA reductase inhibitors (lovastatin, simvastatin; others)Risk of myopathy including rhabdomyolysis; lovastatin and simvastatin contraindicated.DailyMed (U.S. National Library of Medicine)

• Based on animal findings (cardiovascular anomalies in rats, cleft palate in mice at clinically relevant doses), clarithromycin is not recommended in pregnant women except where no alternative therapy is appropriate; limited human data are insufficient to inform drug-associated risk. If pregnancy occurs during treatment, the patient should be informed of the potential hazard to the fetus.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Clarithromycin and 14-OH clarithromycin pass into human milk at less than 2% of the maternal weight-adjusted dose; adverse effects in breastfed infants (rash, diarrhoea, loss of appetite, somnolence) were comparable to amoxicillin. Weigh breastfeeding benefits against maternal need and possible infant effects.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Clarithromycin: Semi-synthetic macrolide (6-O-methylerythromycin) that binds the 50S ribosomal subunit and inhibits bacterial protein synthesis.